Clinical trials: Neuroendocrine Cancer
Medullary Thyroid Cancer
An Initial Study of Lithium in Patients With Medullary Thyroid Cancer
Primary objective is to evaluate the tumor response rate of patients with MTC treated with Lithium carbonate
- Trial name
- NCT00582712
- Testing
- Lithium carbonate
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Neuroendocrine Tumors, Carcinoid Tumors
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
To determine objective response rates (RR) by RECIST guideline version 1.1 for all patients treated with this strategy consisting of initial therapy with pertuzumab as a single agent and then addition of erlotinib for those who…
- Conditions
- Neuroendocrine Tumors, Carcinoid Tumors, Adrenal Gland Tumors, Neuroblastoma
- Trial name
- NCT00947167
- Testing
- pertuzumab, erlotinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Pamela L. Kunz
Melanoma
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
This 2-part study will evaluate the safety and efficacy of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-risk Stage II melanoma.
- Trial name
- NCT03553836
- Testing
- Pembrolizumab
- Where
- 159 sites in United States, Australia and 14 more
- Volunteers
- 976 people
- Sponsor
- Merck Sharp & Dohme LLC
Cancer
Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212
This was an open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK2118436 and GSK1120212 in combination. This study was designed in four parts.
- Trial name
- NCT01072175
- Testing
- GSK2118436, GSK1120212
- Where
- 15 sites in United States, Australia
- Volunteers
- 430 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma (Skin)
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
RATIONALE: Peginterferon (PEG-interferon) alfa-2b may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of PEG-interferon alfa-2b in treating patients who have stage…
- Trial name
- NCT00049530
- Testing
- PEG-interferon alfa-2b
- Where
- 32 sites in United States
- Volunteers
- 32 people
- Sponsor
- Eastern Cooperative Oncology Group
Neuroendocrine Tumors, Neuroendocrine Neoplasm
Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
This is a prospective, multi-centre, open label, non-randomized phase II study evaluating the efficacy and safety of nivolumab plus platinum-based chemotherapy in patients with advanced G3 NENs of the GEP tract or of UK origin.
- Conditions
- Neuroendocrine Tumors, Neuroendocrine Neoplasm, Gastroenteropancreatic Neuroendocrine Tumor
- Trial name
- NCT03980925
- Testing
- Nivolumab, Carboplatin, Etoposide
- Where
- 12 sites in Spain
- Volunteers
- 37 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Malignant Melanoma
Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma
The purposes of this study are to describe the immune response to individual peptides after immunization with a combination of 8 peptides and CpG 7909 or Montanide ISA51; to determine the safety of the vaccines and; to document…
- Trial name
- NCT00145158
- Testing
- 8 HLA-A2-restricted peptides and Montanide ISA51, 8 HLA-A2-restricted peptides and CpG 7909
- Where
- 2 sites in Belgium
- Volunteers
- 23 people
- Sponsor
- Ludwig Institute for Cancer Research
Carcinoid Tumor
Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer.
- Trial name
- NCT01782443
- Testing
- Ziv-aflibercept
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Dana-Farber Cancer Institute
Melanoma
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
The objective of this study is to evaluate the efficacy and safety of treatment with talimogene laherparepvec compared to subcutaneously administered GM-CSF in patients with unresectable Stage IIIb, IIIc and Stage IV melanoma.
- Trial name
- NCT00769704
- Testing
- Talimogene laherparepvec, GM-CSF
- Where
- 83 sites in United States, Canada and 2 more
- Volunteers
- 437 people
- Sponsor
- BioVex Limited
Refractory Cutaneous Melanoma
Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma
The primary objective of this clinical trial is to evaluate the clinical efficacy and progression free survival of the triplet combination of ipilimumab + nivolumab + cabozantinib in patients with anti-PD-1/PD-L1 refractory…
- Trial name
- NCT05200143
- Testing
- Ipilimumab, Nivolumab, Cabozantinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Providence Health & Services
Uveal Melanoma
A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma
IMCgp100-102 is a Phase I/II study of the weekly intra-patient escalation dose regimen with IMCgp100 as a single agent in participants with metastatic uveal melanoma (mUM).
- Trial name
- NCT02570308
- Testing
- IMCgp100
- Where
- 26 sites in United States, Canada and 3 more
- Volunteers
- 146 people
- Sponsor
- Immunocore Ltd
Melanoma
Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
The primary purpose of this study is to evaluate the efficacy of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma
- Trial name
- PLATforM (NCT03484923)
- Testing
- PDR001, LAG525, INC280
- Where
- 30 sites in United States, Australia and 8 more
- Volunteers
- 196 people
- Sponsor
- Novartis Pharmaceuticals
Castration-Sensitive Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
This phase II trial studies how well antiandrogen therapy, abiraterone acetate, and prednisone with or without neutron radiation therapy work in treating patients with prostate cancer.
- Conditions
- Castration-Sensitive Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma
- Trial name
- NCT03649841
- Testing
- Antiandrogen Therapy, Abiraterone Acetate, Prednisone
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Washington
Recurrent Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma
This phase II trial studies how well glembatumumab vedotin works in treating patients with middle layer of the wall of the eye (uveal) melanoma that has spread to other parts of the body (metastatic) or has returned at or near…
- Trial name
- NCT02363283
- Testing
- Glembatumumab Vedotin, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 25 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
This is a Phase III, double-blinded, placebo-controlled, randomized, multicenter study designed to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab + cobimetinib + vemurafenib compared with placebo +…
- Trial name
- NCT02908672
- Testing
- Atezolizumab, Cobimetinib, Vemurafenib
- Where
- 110 sites in United States, Australia and 18 more
- Volunteers
- 514 people
- Sponsor
- Hoffmann-La Roche
Small Cell Neuroendocrine Carcinoma, Prostate Cancer
Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
Despite the low androgen receptor (AR) transcriptional activity of treatment-emergent small cell neuroendocrine prostate cancer, there is persistent AR expression observed in the majority of treatment-emergent small-cell…
- Conditions
- Small Cell Neuroendocrine Carcinoma, Prostate Cancer, Small Cell Carcinoma
- Trial name
- NCT04926181
- Testing
- Apalutamide, Cetrelimab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Rahul Aggarwal
End of Life, Advanced Cancer
Engagement of Patients With Advanced Cancer
The Engagement of Patients with Advanced Cancer is an intervention that utilizes well-trained lay health coaches to engage patients and their families in goals of care and shared decision-making after a diagnosis of advanced…
- Conditions
- End of Life, Advanced Cancer, Lung Neoplasm, Gastric Cancer
- Trial name
- EPAC (NCT02966509)
- Testing
- EPAC
- Volunteers
- 213 people
- Sponsor
- Stanford University
Psoriasis, Melanoma
Can We Miss Pigmented Lesions in Psoriasis Patients?
In psoriasis patients, thick psoriatic plaques can obscure these lesions, and clinicians rely heavily on visual inspection to recognize suspicious or atypical pigmented lesions.
- Conditions
- Psoriasis, Melanoma, Non-melanoma Skin Cancer
- Trial name
- NCT01053819
- Testing
- etanercept
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Adrenal Gland Neoplasms
Evaluation of Molecular Markers in Adrenal Tumors
Background: Tumors of the adrenal gland are common. Most of them are not cancerous. However, there are no tests that can accurately tell which adrenal tumors are cancerous and which are not.
- Trial name
- NCT01348698
- Testing
- Tumor tissue biopsy, Surgery
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Melanoma
A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma
This open-label single arm study will assess the efficacy, safety and tolerability of Vemurafenib in previously treated patients with metastatic melanoma.
- Trial name
- NCT00949702
- Testing
- vemurafenib
- Where
- 15 sites in United States, Australia
- Volunteers
- 132 people
- Sponsor
- Hoffmann-La Roche